Related Experiment Videos
Sarcopenia Predicts the Recompensation in Patients With Decompensated Cirrhosis
Ning Wei1,2, Minghui Liu1, Li Gu3
1Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Clinical and Translational Gastroenterology
|June 9, 2026
Summary
Sarcopenia, a condition of muscle loss, and low hemoglobin levels independently predict the recompensation of decompensated cirrhosis patients. Identifying these factors helps manage high-risk individuals.
Area of Science:
- Hepatology
- Geriatrics
- Clinical Nutrition
Background:
- Sarcopenia is linked to worse outcomes and mortality in liver cirrhosis patients.
- The predictive value of sarcopenia for recompensation in decompensated cirrhosis remains unclear.
- This study investigates sarcopenia's role in predicting recompensation in decompensated cirrhosis.
Purpose of the Study:
- To assess the performance of sarcopenia in predicting recompensation.
- To identify predictors of recompensation in patients with decompensated cirrhosis.
Main Methods:
- Retrospective analysis of 258 patients with decompensated cirrhosis.
- Data collection and statistical analysis including univariate and multivariate logistic regression.
- Evaluation of variables such as L3 skeletal muscle index (SMI) and subcutaneous fat area (SFA).
Main Results:
- 36.82% of patients achieved recompensation.
- Patients without sarcopenia had a higher recompensation rate (41.62%) compared to those with sarcopenia (27.06%).
- Sarcopenia (OR=0.52; p=0.03) and hemoglobin (OR=1.02; p<0.01) were identified as independent predictors of recompensation.
Conclusions:
- Sarcopenia and hemoglobin levels are independent predictors for recompensation in decompensated cirrhosis.
- These findings aid in identifying high-risk patients who may struggle to achieve recompensation.
- Early identification can guide interventions to improve clinical outcomes.
Related Concept Videos
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...